

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : David A. Adler, Paul O. Sheppard
Serial No. : 09/923,236
Group Art Unit : 1652
Examiner : Monshipouri, M.
Filed : August 3, 2001
For : SECRETED SALIVARY ZSIG63 POLYPEPTIDE
Date Submitted : May 10, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.


The present application is a divisional of U.S. Patent Application Serial No. 09/527,345, filed March 17, 2000, now U.S. Patent No. 6,331,413.


Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent and Trademark Office in a prior application identified herein.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 26-0290.

Respectfully submitted,


James M. Bogden
Attorney for Applicants
Registration No. 32,962

FORM PTO
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 98-71D1

Serial No.
09/923,236

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):
David A. Adler, Paul O. SheppardFiling Date:
August 3, 2001

Group: 1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	WO98/45436	10/15/98	PCT			
	A2	WO99/22243	05/06/99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A3		Genbank Accession No. V89597 (Agostino, MJ et al., Genetics Institute, 15 Feb 1999)
	A4		Incyte Pharmaceuticals, Inc. clone, 1996: INC1325518
	A5		Incyte Pharmaceuticals, Inc. clone, 1996: INC1327925
	A6		Incyte Pharmaceuticals, Inc. clone, 1996: INC1326578
	A7		Incyte Pharmaceuticals, Inc. clone, 1996: INC1326831
	A8		Incyte Pharmaceuticals, Inc. clone, 1996: INC1825263
	A9		Incyte Pharmaceuticals, Inc. clone, 1996: INC1825553
	A10		Incyte Pharmaceuticals, Inc. library, 1996: LPARNOT02
	A11		Incyte Pharmaceuticals, Inc. library, 1996: LSUBNOT03

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.